Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The age-related loss of muscle mass and function, sarcopenia, has several deleterious effects, such as a reduction in the quality of life and an increase in the incidence of falls, often leading to hospitalisation. The prevalence of sarcopenia is unclear but is estimated to be between 4.6 and 7.9% and the loss of skeletal muscle mass and function is accelerated in people with type 2 diabetes. With the percentage of older people and the percentage of people with type 2 diabetes predicted to rise in coming years it is crucial to develop therapies to increase muscle mass and function. Alterations in nutrition have also been suggested to be of therapeutic use in sarcopenia. Epidemiological data showed that the consumption of fatty fish is positively associated with muscle function in older population, indicating a potential role for long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in increasing muscle mass and function in older people. The aim of the current study, therefore, is to determine the effects of krill oil supplementation on muscle size and function in adults with muscle weakness and type 2 diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | vegetable oil 4g/day |
|
| Krill Oil | Active Comparator | Krill Oil 4g/day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Krill Oil | Dietary Supplement | Krill oil supplements 4g/day |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Grip strength | Change in Grip strength | Change from baseline to one year |
| Measure | Description | Time Frame |
|---|---|---|
| SPPB | Change in Short performance physical battery test | Change from baseline to one year |
| HbA1c | Change in glycated haemoglobin | Change from baseline to one year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Stuart R Gray | Contact | 01413302569 | stuart.gray@glasgow.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| Ebaa AlOzairi | Dasman Diabetes Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dasman Diabetes Institute | Recruiting | Kuwait City | 15462 | Kuwait |
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D010938 | Plant Oils |
| ID | Term |
|---|---|
| D009821 | Oils |
| D008055 | Lipids |
| D028321 | Plant Preparations |
| D001688 | Biological Products |
Not provided
Not provided
Parallel Group Randomised Controlled Trial
Not provided
Not provided
Double Blind
| Vegetable Oil |
| Dietary Supplement |
vegetable oil supplements 4g/day |
|
| Blood pressure | Change in blood pressure | Change from baseline to one year |
| body mass | Change in body mass | Change from baseline to one year |
| Lean mass | Change in lean mass | Change from baseline to one year |
| Body fat | Change in body fat | Change from baseline to one year |
| BMC | Change in bone mineral content | Change from baseline to one year |
| BMD | Change in bone mineral density | Change from baseline to one year |
| Erythrocyte fatty acid profile | Change in Erythrocyte fatty acid profile | Change from baseline to one year |
| D004700 | Endocrine System Diseases |
| D045424 |
| Complex Mixtures |